Jessica R. Chapman, PhD
Pathologist-Scientist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Mass Spectrometry-Based Proteomics
- Amyloidosis
- Protein Biomarker Analysis
About Me
- Director, Clinical Proteomics
I am a bioanalytical chemist who specializes in mass spectrometric analysis of peptides and proteins. My primary clinical responsibility is the interpretation of mass spectrometry-based proteomics clinical assay results. As a laboratory director, I am responsible for the management and oversight of the Clinical Proteomics Laboratory. This includes the development and validation of novel assays for the identification and quantitation of proteins and peptides that will facilitate precision medicine. I work closely with pathologists and oncologists to identify unmet clinical diagnostic and prognostic needs.
Read more
My current research interests include the development of methods for the detection and quantitation of clinically relevant biomarkers. One specific area of focus are methods for tracking disease in patients with myeloma and Amyloid light-chain (AL) amyloidosis.
A pathologist-scientist is a doctor with special training in researching why a disease happens and how it changes over time.
My Specialties
- Mass Spectrometry-Based Proteomics
- Amyloidosis
- Protein Biomarker Analysis
Education
- PhD, University of Virginia
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Contact and Location
Dr. Chapman sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
View a list of Dr. Chapman’s publications.
Chapman JR, Liu A, Yi SS, Hernandez E, Ritorto MS, Jungbluth AA, Pulitzer M, Dogan A. Proteomic analysis shows that the main constituent of subepidermal localised cutaneous amyloidosis is not galectin-7. Amyloid. 2020 Sep 1;1-7. PMID: 32867548.
Read more
Martins CO, Huet S, Yi SS, Ritorto MS, Landgren O, Dogan A, Chapman JR. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. J Mol Diagn. 2020, 22(7):901-911. PMID: 32302778.
Martins CO, Lezcano C, Yi SS, Landau HJ, Chapman JR, and Dogan, A. Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. Haematologica. 2018, 103(12), e610 – e612. PMID: 30262557
Chapman, J.R., Katsara, O., Ruoff, R., Morgenstern, D., Nayak, S., Basilico, C., Ueberheide, B., and Kolupaeva, V. Phosphoproteomics of FGF1 signaling in chondrocytes: Identifying the signature of inhibitory response. Mol. Cell Proteomics. 2017, 16(6), 1126 – 1137. PMID: 28298517
Chapman, J.R., Balasubramanian, D., Tam, K., Askenazi, M., Copin, R., Shopsin, B., Torres, V.J., and Ueberheide, B. Using quantitative mass spectrometry to better understand the influence of genetics and nutritional perturbations on the virulence potential of Staphylococcus aureus. Mol. Cell Proteomics. 2017, 16(4), S15-S28. PMID: 28196877
Visit PubMed for a full listing of Dr. Chapman’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jessica R. Chapman discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].